RI2 Stock Chart & Stats
€41.49
-€0.54(-1.63%)
At close: 4:00 PM EDT
€41.49
-€0.54(-1.63%)
Day’s Range― - ―
52-Week Range€21.20 - €43.40
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€801.72M
Enterprise Value€710.20
Total Cash (Recent Filing)€95.33M
Total Debt (Recent Filing)€39.95M
Price to Earnings (P/E)2.7
Beta1.07
Next Earnings
Nov 10, 2026EPS Estimate
0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)17.67
Shares Outstanding18,679,865
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.97
Price to Sales (P/S)2.62
P/FCF Ratio10.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€56.70Price Target Upside36.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)2.99
Revenue Forecast (FY)€262.30M
Bulls Say, Bears Say
Bulls Say
Commercial Product GrowthGrowth across the commercial portfolio indicates expanding demand beyond a single product, supporting a more durable revenue base. TAVALISSE’s record quarter and REZLIDHIA’s faster growth can improve operating leverage and provide resources for continued development and commercialization.
Positive Cash GenerationThe shift from negative operating and free cash flow in earlier years to substantial positive generation strengthens Rigel’s ability to fund development internally. This reduces reliance on external financing and supports ongoing investment while preserving greater strategic flexibility.
VEPPANU Commercial OpportunityThe VEPPANU license adds a differentiated oncology product to Rigel’s portfolio and expands its addressable market beyond existing hematology products. If launch execution and adoption meet expectations, the asset could materially diversify revenue and become a major long-term growth driver.
Bears Say
VEPPANU Financial ObligationsVEPPANU’s substantial upfront, milestone, royalty, and development commitments can absorb cash and reduce the economic benefit of future sales. These obligations may pressure margins during commercialization and limit flexibility to fund other pipeline programs or respond to setbacks.
Declining Recent Revenue TrendThe latest trailing revenue decline suggests that recent commercial momentum has not yet translated into consistently expanding company-wide sales. A sustained contraction would weaken operating leverage and make the success of new products, particularly VEPPANU, more important to future growth.
Higher Operating CostsRapid expense growth can reduce the durability of improved profitability if spending rises faster than recurring product revenue. Higher R&D, product, and personnel costs also increase the execution burden, requiring successful launches and pipeline progress to sustain earnings and cash generation.
Rigel News
RI2 FAQ
What was Rigel’s price range in the past 12 months?
Rigel lowest stock price was €21.20 and its highest was €43.40 in the past 12 months.
What is Rigel’s market cap?
Rigel’s market cap is €801.72M.
When is Rigel’s upcoming earnings report date?
Rigel’s upcoming earnings report date is Nov 10, 2026 which is in 47 days.
How were Rigel’s earnings last quarter?
Rigel released its earnings results on Aug 04, 2026. The company reported €0.76 earnings per share for the quarter, beating the consensus estimate of €0.076 by €0.684.
Is Rigel overvalued?
According to Wall Street analysts Rigel’s price is currently Undervalued.
Does Rigel pay dividends?
Rigel does not currently pay dividends.
What is Rigel’s EPS estimate?
Rigel’s EPS estimate is 0.8.
How many shares outstanding does Rigel have?
Rigel has 18,679,865 shares outstanding.
What happened to Rigel’s price movement after its last earnings report?
Rigel reported an EPS of €0.76 in its last earnings report, beating expectations of €0.076. Following the earnings report the stock price went up 7.593%.
Which hedge fund is a major shareholder of Rigel?
Currently, no hedge funds are holding shares in DE:RI2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rigel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€56.70 (36.66% Upside)
€56.70 (36.66% Upside)
Blogger Sentiment
Bullish
DE:RI2 Sentiment 83%
Sector Average 63%
Sector Average 63%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.47%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
152.04%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Rigel
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
RI2 Company Deck
RI2 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple meaningful commercial and pipeline achievements—most notably the in‑license and imminent launch of VEPPANU with strong phase III efficacy, ongoing commercial revenue growth (14% product sales growth, record TAVALISSE quarter, 27% REZLIDHIA growth), and promising early R289 data with regulatory incentives. These positives are tempered by lower year‑over‑year net income (partly due to one‑time prior‑year items), a substantial decline in cash reserves (~38.5%), higher operating expenses (+~35.7%), modest decline in GAVRETO sales, and significant upfront/milestone/royalty obligations tied to VEPPANU that may pressure margins and cash flow. Overall, the company communicated confident launch readiness and an optimistic strategic trajectory but with near‑term financial and execution risks to monitor.View all DE:RI2 earnings summariesRI2 Stock 12 Month Forecast
Average Price Target
€56.70
▲(36.66% Upside)